Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyNet Income towards Common StockholdersOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

ProQR Therapeutics (PRQR) Net Income towards Common Stockholders (2021 - 2025)

Historic Net Income towards Common Stockholders for ProQR Therapeutics (PRQR) over the last 5 years, with Q3 2025 value amounting to -$12.9 million.

  • ProQR Therapeutics' Net Income towards Common Stockholders fell 3836.62% to -$12.9 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$48.3 million, marking a year-over-year decrease of 8678.42%. This contributed to the annual value of -$30.0 million for FY2024, which is 120.94% up from last year.
  • ProQR Therapeutics' Net Income towards Common Stockholders amounted to -$12.9 million in Q3 2025, which was down 3836.62% from -$14.6 million recorded in Q2 2025.
  • Over the past 5 years, ProQR Therapeutics' Net Income towards Common Stockholders peaked at -$2.9 million during Q2 2024, and registered a low of -$23.5 million during Q3 2022.
  • For the 5-year period, ProQR Therapeutics' Net Income towards Common Stockholders averaged around -$12.6 million, with its median value being -$12.9 million (2025).
  • Its Net Income towards Common Stockholders has fluctuated over the past 5 years, first surged by 7201.08% in 2023, then crashed by 40218.09% in 2025.
  • Quarter analysis of 5 years shows ProQR Therapeutics' Net Income towards Common Stockholders stood at -$20.8 million in 2021, then skyrocketed by 34.92% to -$13.6 million in 2022, then surged by 60.85% to -$5.3 million in 2023, then plummeted by 85.19% to -$9.8 million in 2024, then crashed by 31.09% to -$12.9 million in 2025.
  • Its Net Income towards Common Stockholders was -$12.9 million in Q3 2025, compared to -$14.6 million in Q2 2025 and -$11.0 million in Q1 2025.